Cost-effectiveness of raloxifene in the UK: An economic evaluation based on the MORE study

Osteoporosis International

Volumn 16, Issue 1, 2005, Pages 15-25

  Kanis, J A ^a   Borgstrom F ^b   Johnell, O ^c   Oden, A ^d   Sykes, D ^e   Jonsson B ^f  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b STOCKHOLM HEALTH ECONOMICS   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Consulting Statistician ^*  (Sweden)

^e ELI LILLY AND COMPANY   (United States)

^f STOCKHOLM SCHOOL OF ECONOMICS   (Sweden)

Author keywords

Breast cancer; Cost effectiveness; Raloxifene; Vertebral fracture

Indexed keywords

CALCIUM; PLACEBO; RALOXIFENE; VITAMIN D;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; COMPUTER SIMULATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; ECONOMIC ASPECT; FEMALE; FRAGILITY FRACTURE; HUMAN; MAJOR CLINICAL STUDY; OUTCOMES RESEARCH; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZATION; SIDE EFFECT; UNITED KINGDOM; VENOUS THROMBOEMBOLISM; VERTEBRA FRACTURE;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; ESTROGEN ANTAGONISTS; FEMALE; GREAT BRITAIN; HUMANS; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; QUALITY OF LIFE; RALOXIFENE; RISK FACTORS; SPINAL FRACTURES; TREATMENT OUTCOME;

EID: 13244277629     PISSN: 0937941X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00198-004-1688-0     Document Type: Article

References (62)

1. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
2. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC (1999) The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA 281:2189-2197
3. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, Harper KD (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. JAMA 287:847-857
4. Raftery J (2001) NICE: faster access to modern treatments? Analysis of guidance on health technologies. BMJ 323:1300-1303
5. Johannesson M, Hedbrant J and Jonsson B (1991) A computer simulation model for cost-effectiveness analysis of cardiovascular disease prevention. Med Inform (Lond) 16:355-362
6. Zethraeus N, Johannesson M, Jonsson B (1999) A computer model to analyze the cost-effectiveness of hormone replacement therapy. Int J Technol Assess Health Care 15:352-365
7. Kanis JA, Dawson A, Oden A, Johnell O, de Laet C, Jonsson B (2001) Cost-effectiveness of preventing hip fracture in the general female population. Osteoporos Int 12:356-361
8. Kanis JA, Johnell O, Oden A, De Laet C, Jonsson B, Dawson A (2002) Ten-year risk of osteoporotic fracture and the effect of risk factors on screening strategies. Bone 30:251-258
9. Kanis JA, Johnell O, Oden A, De Laet C, Oglesby A, Jonsson B (2002) Intervention thresholds for osteoporosis. Bone 31:26-31
10. Kanis JA, Johnell O, Oden A, Jonsson B, Dawson A, Dere W (2000) Risk of hip fracture derived from relative risks: an analysis applied to the population of Sweden. Osteoporos Int 11:120-127
11. Zethraeus N, Ben Sedrine W, Caulin F, Corcaud S, Gathon HJ, Haim M, Johnell O, Jonsson B, Kanis JA, Tsouderos Y, Reginster JY (2002) Models for assessing the cost-effectiveness of the treatment and prevention of osteoporosis. Osteoporos Int 13:841-857
12. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, Farrerons J, Karasik A, Mellstrom D, Ng KW, Stepan JJ, Powles TJ, Morrow M, Costa A, Silfen SL, Walls EL, Schmitt H, Muchmore DB, Jordan VC, Ste-Marie LG (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125-134
13. Delmas PD, Ensrud KE, Adachi JD, Harper KD, Sarkar S, Gennari C, Reginster JY, Pols HA, Recker RR, Harris ST, Wu W, Genant HK, Black DM, Eastell R (2002) Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab 87:3609-3617
14. Lothgren M, Zethraeus N (2000) Definition, interpretation and calculation of cost-effectiveness acceptability curves. Health Econ 9:623-630
15. Neele SJ, Evertz R, De Valk-De Roo G, Roos JC, Netelenbos JC (2002) Effect of 1 year of discontinuation of raloxifene or estrogen therapy on bone mineral density after 5 years of treatment in healthy postmenopausal women. Bone 30:599-603
16. Michaelsson K, Baron JA, Farahmand BY, Johnell O, Magnusson C, Persson PG, Persson I, Ljunghall S (1998) Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 316:1858-1863
17. Felson DT, Zhang Y, Hannan MT, Kiel DP, Wilson PW, Anderson JJ (1993) The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 329:1141-1146
18. Stevenson JC, Kanis JA, Christiansen C (1992) Bone-density measurement. Lancet 339:370-371
19. Million Women Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419-427
20. Kanis JA, Johnell O, Oden A, Sembo I, Redlund-Johnell I, Dawson A, De Laet C, Jonsson B (2000) Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int 11:669-674
21. Felsenberg D, Silman A, Lunt M, Ambrecht G, Ismail A (2002) Incidence of Vertebral Fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res 17:716-724
22. Marshall D, Johnell O, Wedel H (1996) Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312:1254-1259
23. Klotzbuecher CM, Ross PD, Landsman PB, Abbott TA 3rd, Berger M (2000) Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Miner Res 15:721-739
24. Cancer Statistics Registrations - Registrations of cancer diagnosed in 1998, England. Office for National Statistics: London, 2002
25. Cauley JA, Lucas FL, Kuller LH, Vogt MT, Browner WS, Cummings SR (1996) Bone mineral density and risk of breast cancer in older women: the study of osteoporotic fractures. Study of Osteoporotic Fractures Research Group. JAMA 276:1404-1408
26. Zhang Y, Kiel DP, Kreger BE, Cupples LA, Ellison RC, Dorgan JF, Schatzkin A, Levy D, Felson DT (1997) Bone mass and the risk of breast cancer among postmenopausal women. N Engl J Med 336:611-617
27. Kannel W, Wolf P, Garrison R (1987) The Framingham study: an epidemiological investigation of cardiovascular disease. US Department of Commerce National Technical Information Service, Springfield
28. Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM and Melton LJ 3rd (1998) Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch hit Med 158:585-593
29. Technology Appraisals Series No. 5: Guidance for Manufacturers and Sponsors (2001) National Institute for Clinical Excellence
30. Dolan P, Torgerson DJ (1998) The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8:611-617
31. Kanis J, Brazier J, Stevenson M, Calvert W, Jones ML (2002) Treatment of established osteoporosis: a systematic review and cost-utility analysis. Health Technology Assessment 6:1-146
32. De Laet CE, van Hout BA, Burger H, Weel AE, Hofman A, Pols HA (1999) Incremental cost of medical care after hip fracture and first vertebral fracture: the Rotterdam study. Osteoporos Int 10:66-72
33. Hutton J, Brown R, Borowitz M, Abrams K, Rothman M, Shakespeare A (1996) A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. Pharmacoeconomics 9 Suppl 2:8-22
34. Sanderson C, Kubin M (2001) Prevention of coronary heart disease through treatment of infection with Chlamydia pneumoniae? Estimation of possible effectiveness and costs. Health Care Manag Sci 4:269-279
35. Daly E, Vessey MP, Barlow D, Gray A, McPherson K, Roche M (1996) Hormone replacement therapy in a risk-benefit perspective. Maturitas 23:247-259
36. Netten A, Rees T, Harrison G (2001) Unit costs of health and Social Care. Personal Social Services Research Unit, University of Kent. www.ukc.ac.uk/PSSRU/
37. Zethraeus N, Borgström F, Johnell I, Kanis JA, Jönsson B (2002) Costs and quality of life associated with osteoporosis related fractures-results from a Swedish survey. Working Paper Series in Economics and Finance, 512
38. Lundberg L (1999) Health-related quality of life in Sweden. Faculty of Pharmacy, Uppsala University
39. Kanis J, Johnell O, Oden A, Borgström F, Zethraeus N, Laet CD, Jönsson B (2004) The risk and burden of vertebral fracture in Sweden. Osteoporosis Int 15:20-26
40. Kind P, Dolan P, Gudex C, Williams A (1998) Variations in population health status: results from a United Kingdom national questionnaire survey. BMJ 316:736-741
41. Johnell O, Jonsson B, Jonsson L, Black D (2003) Cost effectiveness of alendronate (fosamax) for the treatment of osteoporosis and prevention of fractures. Pharmacoeconomics 21:305-314
42. Iglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 95:305-311
43. Johannesson M (1995) The cost effectiveness of hypertension treatment in Sweden. Pharmacoeconomics 7:242-250
44. Interim Life Tables (2002) Government Actuary's Department
45. Cauley JA, Thompson DE, Ensrud KC, Scott JC, Black D (2000) Risk of mortality following clinical fractures. Osteoporos Int 11:556-561
46. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA (1999) Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 353:878-882
47. Cooper C, Atkinson EJ, Jacobsen SJ, O'Fallon WM, Melton LJ 3rd (1993) Population-based study of survival after osteoporotic fractures. Am J Epidemiol 137:1001-1005
48. Johnell O, Kanis JA, Odén A, Sernbo I, Redlund-Johnell I, Petterson C, Laet CD, Jönsson B (2004) Mortality after osteoporotic fractures. Osteoporos Int 15:38-42
49. Heit JA, Mohr DN, Silverstein MD, Petterson TM, O'Fallon WM, Melton LJ 3rd (2000) Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Int Med 160:761-768
50. Kearon C (2003) Natural history of venous thromboembolism. Circulation 107:122-130
51. Frost ML, Blake GM, Fogelman I (2001) Quantitative ultrasound and bone mineral density are equally strongly associated with risk factors for osteoporosis. J Bone Miner Res 16:406-416
52. Kanis JA, Johnell O, Oden A, Jonsson B, De Laet C, Dawson A (2000) Risk of hip fracture according to the World Health Organization criteria for osteopenia and osteoporosis. Bone 27:585-590
53. Kanis J, Johnell O, Black D, Downs R, Sarkar S, Feurst T, Secrest R, Pavo I (2003) Effect of raloxifene on the risk of new vertebral fracture in postmenopausal women defined by total hip bone mineral density. Bone 33:293-300
54. Stock JL, Bell NH, Chesnut CH 3rd, Ensrud KE, Genant HK, Harris ST, McClung MR, Singer FR, Yood RA, Pryor-Tillotson S, Wei L, Santora AC 2nd (1997) Increments in bone mineral density of the lumbar spine and hip and suppression of bone turnover are maintained after discontinuation of alendronate in postmenopausal women. Am J Med 103:291-297
55. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
56. Bagger YZ, Tanko LB, Alexandersen P, Hansen HB, Mollgaard A, Ravn P, Qvist P, Kanis JA, Christiansen C (2004) Two to three years of hormone replacement treatment in healthy women have long-term prevention effects on bone mass and osteoporotic fractures: the PERF study. Bone 34:728-735
57. Jalava T, Sarna S, Pylkkanen L, Mawer B, Kanis JA, Selby P, Davies M, Adams J, Francis RM, Robinson J, McCloskey EV (2003) Association between vertebral fracture and increased mortality in osteoporotic patients. J Bone Miner Res 18:1254-1260
58. National Osteoporosis Foundation (1998) Osteoporosis: review of the evidence for prevention, diagnosis and treatment and cost-effective analysis. Osteoporos Int 8 (Suppl 4):1-88
59. Brazier JE, Green C, Kanis JA (2002) A systematic review of health state utility values for osteoporosis-related conditions. Osteoporos Int 13:768-776
60. Inglesias CP, Torgerson DJ, Bearne A, Bose U (2002) The cost utility of bisphosphonate treatment in established osteoporosis. Q J Med 95:305-311
61. Kanis JA, Borgstrom F, Johnell O, Jonsson B (2004) Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women. Osteoporos Int (in press)
62. Borgstrom F, Johnell O, Kanis JA, Oden A, Sykes D, Jonsson B (2004) Cost-effectiveness of raloxifene in Sweden. An economic evaluation based on the MORE study. Pharmacoeconomics (in press)